ADVERTISEMENT
Former FDA Commissioner Frank Young Dies
Former FDA Commissioner Frank Young Dies
The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.
Former FDA Commissioner Frank Young Dies
Former FDA Commissioner Frank Young Dies

The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.

The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.

biotech, pharma

CRISPR Patent Dispute Heard in Federal Court
Jim Daley | May 1, 2018 | 2 min read
In an ongoing legal battle, the University of California, Berkeley has challenged the Broad Institute’s patent claims on the gene editing technology.
The Growth of Iowa Biotech
Jenny Rood | Aug 1, 2016 | 7 min read
The state’s industry draws inspiration from medicine as well as agriculture.
Starting a New Lab
The Scientist | 1 min read
Advice for new principal investigators starting their first research laboratories!
$1.5 Billion Pharma Buyout for Leukemia Drug
Jef Akst | Jun 1, 2016 | 1 min read
Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.
Biotech Stocks Take a Hit
Kerry Grens | Sep 30, 2015 | 2 min read
Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.
Hearing Help
Kate Yandell | Sep 1, 2015 | 10+ min read
For decades, the only remedies for hearing loss were devices such as hearing aids or cochlear implants. Now, the first pharmaceutical treatments may be on the way.
 
Lazarus Drugs
Kate Yandell | Feb 1, 2015 | 8 min read
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.
 
Roche Buys Biotech for $8.3B
Jef Akst | Aug 27, 2014 | 1 min read
The pharma giant strikes a deal to acquire InterMune, a Brisbane, California-based biotech with only one product—a treatment for a fatal lung disease.
Merck Snaps Up Biotech for $3.85B
Tracy Vence | Jun 10, 2014 | 1 min read
The drug giant will acquire Cambridge, Massachusetts-based Idenix Pharmaceuticals, which is focused on developing treatments for hepatitis C.
Best Places to Work Industry 2013
The Scientist | Jun 1, 2013 | 6 min read
Our final survey of the life-science industry workplace highlights the companies—small and large, domestic and international—that are making their researchers feel valued and at home.
BPTW: By The Numbers
The Scientist | May 31, 2013 | 1 min read
Take a closer look at some of the statistics generated by The Scientist's Best Place to Work Industry 2013 survey.
Start It Up
Dan Cossins | Apr 1, 2013 | 8 min read
Young researchers who left the academic path to transform their bright ideas into thriving companies discuss their experiences, and how you can launch your own business.
Opinion: On the Up and Up
Sean E. Harper | Jun 20, 2012 | 2 min read
An Amgen executive refutes accusations that the company published misleading results of its mid-90s clinical trial testing an anemia drug.
Pharma Puts Up Money for Biotech
Jef Akst | Mar 21, 2012 | 2 min read
GlaxoSmithKline and Johnson & Johnson contribute a total of $100 million to early-stage biotech endeavors.
Self-prescribing Patients?
Jef Akst | Mar 13, 2012 | 1 min read
The FDA considers making some drugs for diabetes, asthma, and other ailments available over the counter.
Opinion: A Big Pharma Biotech Fund
Mark Kessel | Mar 5, 2012 | 4 min read
Pharmaceutical companies should deploy cash to fund struggling biotech companies, which could generate much needed new drugs.
Female Frontrunners
Jef Akst | Feb 1, 2012 | 7 min read
How to successfully surmount the challenges women face in becoming biotech industry leaders
The Companies that Failed
Edyta Zielinska | Dec 20, 2011 | 3 min read
A roundup of eight biotech companies that didn’t make it through this year's continuing tough economic times
Universities Roll-back Pharma’s Fees
Edyta Zielinska | Dec 20, 2011 | 1 min read
Research universities are removing the licensing fees they charged industry companies for working with their scientists.
ADVERTISEMENT